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INTRODUCTION 
Coronavirus is a spherical or pleomorphic enveloped 
particulate containing a single-stranded [positive sense] 
RNA associated with a capsid nucleoprotein consisting 
of a matric protein. The envelope carries a club-shaped 
glycoprotein projection. It belongs to the Phylum 
Pisuviricota, the Nidovirales order, the Coronaviridae 
family, and the Betacoronavirinae genera (Pal et al., 2020). 
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 Abstract 
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
which was originally known as a virus that infects animals and rarely 
can be transmitted to humans in large populations, is now 
transformed into one of the most feared pandemics causes worldwide. 
Infection by a virus that is officially known as COVID-19 has caused 
global concern mainly due to the number of deaths caused. Since it 
was first reported in Wuhan, China in December 2019, now COVID-
19 has spread to almost all parts of the world with a very rapid spread 
rate. The main symptom of this infection is a respiratory disease 
accompanied by other symptoms that resemble flu-like illness. 
Everyone can suffer from COVID-19, but the elderly, toddlers, 
pregnant women, and people with certain diseases and disorders of 
the immune system show more severe symptoms. The disease is 
transmitted through inhalation or contact with droplets, where the 
incubation period ranges from 2 to 14 days. Until now, specific therapy 
to treat COVID-19 has not been found, with preventive measures 
taken to control its spread. In this mini-review, we will explain 
important information related to COVID-19. 
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Their viral RNA genome is 26 to 32 kilobases in length. It 
is a highly diffuse virus spread by droplets, direct contact, 
and contact with infected objects (Chen et al., 2020). 
Coronavirus is a large family of viruses that can infect 
birds and mammals, including humans, according to the 
World Health Organization. The virus is responsible for 
causing severe acute respiratory syndrome (SARS) 
(Raoult et al., 2020; Woo et al., 2010). 
On January 24th, 2020, at least 830 cases were diagnosed 
in nine countries: China, Thailand, Japan, South Korea, 
Singapore, Nepal, Vietnam, and Taiwan (Tan et al., 2020). 
And by the end of December 2019, a virus from a similar 
family group had re-emerged in Wuhan and had even 
become a global pandemic (Mackenzie & Smith, 2020). 
The virus was officially named 2019 novel coronavirus 
(2019-nCoV) and is also known as SARS-CoV-2 (Wang et 
al., 2020). Therapies that have proven to be particularly 
effective in the treatment of SARS-CoV-2 infection, 
known as coronavirus disease 2019 (COVID-19), have 
not yet been identified and are still being extensively 
studied by scientists around the world (Yi et al., 2020). 
In this mini-review, we will discuss all kinds of ins and 
outs related to SARS-CoV-2 along with the COVID-19 
outbreak that threatens all human beings in the world, 
starting with the classification and transmission of SARS-
CoV-2, diagnosis, symptoms, management, and 
prevention of COVID-19. The whole discussion will be 
presented with a new perspective, with actual and 
relevant references. 
 
CORONAVIRUS CLASSIFICATION 
The classification of SARS-CoV-2 is shown in Figure 1. In 
general, SARS-CoV-2 has the same beta coronavirus 
genera as SARS-CoV which causes SARS and MERS-
CoV which causes MERS. However, the lineage/strain 
difference causes SARS-CoV-2 to show more 
pathogenicity than both (Pal et al, 2020). Besides, there are 
also several species of coronavirus that specifically infect 
humans, including Human coronavirus 229E (HCoV-
229E), Human coronavirus NL63 (HCoV-NL63), 
Human coronavirus OC43 (HCoV-OC43), and Human 
coronavirus HKU1 (HCoV-N43) (Liu et al., 2020). 
 
Figure 1. Classification and origins of SARS-CoV-2 (Pal et al., 
2020) 
 
COVID-19 TRANSMISSION 
COVID-19 is transmitted through droplets from the 
physiological fluids of infected individuals and can be 
transmitted with various droplet sizes when the droplet 
particle size is > 5-10 μm, the other droplets are 
transmitted through the respiratory tract, and when the 
droplet particles are < 5 μm in diameter, they are referred 
to as the core droplets (Atkinson et al., 2009). According to 
current evidence, COVID-19 is mainly transmitted 
between people via respiratory droplets and direct 
contact routes. Droplet transmission occurs when a 
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person is in close contact with a radius of 1 m with 
someone who has symptoms of respiratory distress, 
where the individual is at risk of inhaling droplets and is 
exposed to oral/nasal mucosa or eye conjunctiva and is 
also exposed to SARS-CoV-2 (Wilson et al., 2020). 
Transmission can also occur through fomites in the 
immediate vicinity of infected people (Huang et al., 2020). 
Some types of coronavirus that infect animals such as cat 
coronavirus (FeCoV) may spread through contact with 
the face. However, it is not clear whether this also applies 
to humans (Weiss & Navas-Martin, 2005). 
 
COVID-19 DIAGNOSIS 
The U.S. CDC has developed criteria for persons under 
investigation (PUIs). If a person is considered to be a PUI, 
immediate prevention, infection, and control measures 
shall be taken. Epidemiological factors are used to assess 
the test requirement. These include close contact with a 
laboratory-confirmed patient with 14 days of symptoms 
or a history of travel to the infected area within 14 days of 
onset on symptoms (Ghinai et al., 2020; Yin & 
Wunderink, 2018). 
Chest X-rays (CXRs) usually show bilateral infiltration 
but may be normal in early illness. Computed 
Tomography (CT) is more sensitive and more specific. 
The CT imagery generally shows infiltrates, ground 
opacities, and sub-segmental consolidation. It is also 
abnormal in asymptomatic patients who have no clinical 
evidence of lower respiratory tract involvement. 
Abnormal CT scans were used to diagnose COVID-19 in 
suspected cases with a negative molecular diagnosis; 
many of these patients had positive re-test molecular tests 
(Cascella et al., 2020). 
 
COVID-19 SYMPTOMS 
In general, the signs and symptoms are shown in people 
suffering from COVID-19 almost resemble the 
symptoms that are shown in cases of other viral 
infections such as fever, dry cough, and muscle aches 
(Singhal, 2020). Therefore, people often do not realize that 
they are infected with COVID-19 because they feel that 
they have other diseases. Some patients show no clinical 
symptoms at all (Raoult et al., 2020; Cascella et al., 2020). 
However, of the majority of cases that occur, it is reported 
that people who are infected show symptoms of flu-like 
illness, such as: 
Most common 
1. Fever 
2. Dry cough 
3. Tiredness 
Less common 
1. Muscle aches 
2. Sore throat 
3. Diarrhea 
4. Conjunctivitis 
5. Headache 
6. Loss of taste or smell 
7. Rash on skin 
From these symptoms, some people show severe 
symptoms and require immediate medical attention, 
including: 
1. Shortness of breath 
2. Chest pain 
3. Difficulty in communication 
It takes 5–6 days, on average, to have symptoms from 
someone infected by the virus, but it may take up to 14 
days (World Health Organization, 2020a). 
 
COVID-19 MANAGEMENT 
As of the end of May 2020 at the time this article was 
written, effective treatments to cure COVID-19 infections 
have not yet been found. Various pharmaceutical 
companies and research groups are still developing 
vaccines and repurposing drug compounds to find the 
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most effective and optimal treatment for COVID-19 
(Amawi et al., 2020; Savi et al., 2020; Wu et al., 2020). The 
management of COVID-19 patients is prioritized based 
on the condition of each patient, where patients who 
have only mild symptoms or no symptoms at all are 
recommended to improve the body's immune system 
and treat the mild symptoms that arise (Ali & Alharbi, 
2020). While in patients with medium and severe 
conditions, also given supportive therapy such as 
administration of antipyretic and analgesic, maintenance 
of hydration, and administration of oxygen. Medical 
therapy involving corticosteroids and antivirals has also 
been encouraged as part of critical management schemes. 
However, there is currently no specific antiviral 
recommended for the treatment of COVID-19 (Nicola et 
al., 2020). In patients with COVID-19 with severe 
conditions and experiencing acute respiratory distress 
syndrome (ARDS), the use of a ventilator as a respiratory 
aid is mandatory and crucial. However, not all health 
facility units have sufficient ventilators, while ventilators 
that are used incorrectly can increase the patient's 
mortality rate (Iyengar et al., 2020; Möhlenkamp & Thiele, 
2020). 
 
COVID-19 PREVENTION 
In addition to using masks and face shields, prevention 
of transmission of COVID-19 is done by maintaining a 
safe distance between people to avoid direct contact with 
droplets that may contain viruses (Perencevich et al., 
2020). Washing your hands as often as possible using 
soap and running water is also mandatory, and if not 
available, it can be replaced with alcohol-based hand 
sanitizers. Equally important is avoiding traveling to a 
place where it is crowded with people (Jayaweera et al., 
2020). Some ways to prevent the spread of COVID-19 as 
summarized by the World Health Organization (2020b) 
include: 
1. Clean your hands up often. Use soap and water, or 
rub a hand based on alcohol. 
2. Keep a safe distance from anyone who's coughing or 
sneezing. 
3. Don't touch your eyes, your nose, or your mouth. 
4. If you cough or sneeze, cover your nose and mouth 
with your bent elbow or tissue. 
5. Stay at home if you feel uneasy. 
6. If you have fever, cough, or difficulty breathing, seek 
medical attention. Please call in advance. 
7. Follow the instructions of your local health authority. 
 
CONCLUSION 
Findings show that large portions of the study participant 
are aware and knowledgeable about COVID-19 and its 
presence in Nigeria. Results obtained from the research 
questions regarding knowledge of COVID-19 in terms of 
respondents' knowledge of the source, transmission, 
symptoms, preventive behavior, the fatality rate of the 
COVID-19, and the major resources of information about 
COVID-19 among north-central Nigerians were 
significantly high. A large portion of the study participant 
is scared of the COVID-19 pandemic and its outbreak in 
Nigeria this may be a result of the high rate of a fatality 
caused by this pandemic worldwide. This could imply 
that the respondents apprehend about COVID-19. The 
knowledge on COVID-19 could, therefore, support a 
better capacity to adopt precautionary measures leading 
to the control of the disease as was in the case of ebola. 
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